Literature DB >> 28233242

Ambiguities in the Guidelines for the Management of Arterial Hypertension: Indian Perspective with a Call for Global Harmonization.

Harmeet Singh Rehan1, Abhinav Grover2, A P S Hungin3.   

Abstract

Many medical professional societies have formulated guidelines to treat hypertension, but there existed differences with respect to diagnosis, blood pressure (BP) targets, pharmacotherapy of hypertension, and grades of evidence. A MEDLINE search for hypertension guidelines was performed to compare Indian guidelines for hypertension (IGH) with these guidelines. A majority of the guidelines had consensus on the cutoff value (140/90 mmHg, recorded twice) to diagnose hypertension. The Joint National Committee 8 (JNC 8), IGH, Japanese Society of hypertension (JSH), Canadian Hypertension Education Program (CHEP), and American Society of Hypertension/International Society of Hypertension (ASH/ISH) guidelines provide a higher BP target for the elderly hypertensive populations, while the National Institute for Health and Care Excellence (NICE) and European Society of Hypertension (ESH) guidelines provided a lower BP target for the elderly patients. However, a meta-analysis showed benefits of having a systolic BP target of <130 mmHg for all patients. Treatment of hypertension according to JNC 8, NICE, and ASH/ISH guidelines varies among the black and the non-black population which recommended thiazide or calcium channel blockers for the black population. There is no special mention of pharmacotherapy or BP targets for the South Asian population in various guidelines including IGH despite evidence of higher risk of hypertension-associated complications in this population. It is suggested that all the available guidelines should be harmonized with highest level of evidence available to minimize ambiguities associated with management of hypertension.

Entities:  

Keywords:  Blood pressure; Guidelines; Hypertension

Mesh:

Substances:

Year:  2017        PMID: 28233242     DOI: 10.1007/s11906-017-0715-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  29 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators.

Authors:  F Gueyffier; F Boutitie; J P Boissel; S Pocock; J Coope; J Cutler; T Ekbom; R Fagard; L Friedman; M Perry; R Prineas; E Schron
Journal:  Ann Intern Med       Date:  1997-05-15       Impact factor: 25.391

Review 4.  The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Authors:  Kaberi Dasgupta; Robert R Quinn; Kelly B Zarnke; Doreen M Rabi; Pietro Ravani; Stella S Daskalopoulou; Simon W Rabkin; Luc Trudeau; Ross D Feldman; Lyne Cloutier; Ally Prebtani; Robert J Herman; Simon L Bacon; Richard E Gilbert; Marcel Ruzicka; Donald W McKay; Tavis S Campbell; Steven Grover; George Honos; Ernesto L Schiffrin; Peter Bolli; Thomas W Wilson; Patrice Lindsay; Michael D Hill; Shelagh B Coutts; Gord Gubitz; Mark Gelfer; Michel Vallée; G V Ramesh Prasad; Marcel Lebel; Donna McLean; J Malcolm O Arnold; Gordon W Moe; Jonathan G Howlett; Jean-Martin Boulanger; Pierre Larochelle; Lawrence A Leiter; Charlotte Jones; Richard I Ogilvie; Vincent Woo; Janusz Kaczorowski; Kevin D Burns; Robert J Petrella; Swapnil Hiremath; Alain Milot; James A Stone; Denis Drouin; Kim L Lavoie; Maxime Lamarre-Cliche; Guy Tremblay; Pavel Hamet; George Fodor; S George Carruthers; George B Pylypchuk; Ellen Burgess; Richard Lewanczuk; George K Dresser; S Brian Penner; Robert A Hegele; Philip A McFarlane; Milan Khara; Andrew Pipe; Paul Oh; Peter Selby; Mukul Sharma; Debra J Reid; Sheldon W Tobe; Raj S Padwal; Luc Poirier
Journal:  Can J Cardiol       Date:  2014-02-22       Impact factor: 5.223

5.  [Diagnosis and treatment of arterial hypertension. 2012 Guidelines of the Czech Hypertension Society].

Authors:  J Filipovský; J Widimský; J Ceral; R Cífková; K Horký; A Linhart; V Monhart; H Rosolová; J Seidlerová; M Souček; J Spinar; J Vítovec; J Widimský
Journal:  Vnitr Lek       Date:  2012-10

Review 6.  Clinical management of drug-induced hypertension: 2013 Practical Recommendations of the Italian Society of Hypertension (SIIA).

Authors:  Agostino Virdis; Lorenzo Ghiadoni; Stefano Taddei
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-02-18

7.  Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

Authors:  Eva M Lonn; Jackie Bosch; Patricio López-Jaramillo; Jun Zhu; Lisheng Liu; Prem Pais; Rafael Diaz; Denis Xavier; Karen Sliwa; Antonio Dans; Alvaro Avezum; Leopoldo S Piegas; Katalin Keltai; Matyas Keltai; Irina Chazova; Ron J G Peters; Claes Held; Khalid Yusoff; Basil S Lewis; Petr Jansky; Alexander Parkhomenko; Kamlesh Khunti; William D Toff; Christopher M Reid; John Varigos; Lawrence A Leiter; Dora I Molina; Robert McKelvie; Janice Pogue; Joanne Wilkinson; Hyejung Jung; Gilles Dagenais; Salim Yusuf
Journal:  N Engl J Med       Date:  2016-04-02       Impact factor: 91.245

Review 8.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.

Authors:  Xinfang Xie; Emily Atkins; Jicheng Lv; Alexander Bennett; Bruce Neal; Toshiharu Ninomiya; Mark Woodward; Stephen MacMahon; Fiona Turnbull; Graham S Hillis; John Chalmers; Jonathan Mant; Abdul Salam; Kazem Rahimi; Vlado Perkovic; Anthony Rodgers
Journal:  Lancet       Date:  2015-11-07       Impact factor: 79.321

9.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

Review 10.  Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review.

Authors:  Lizzy M Brewster; Yackoob K Seedat
Journal:  BMC Med       Date:  2013-05-30       Impact factor: 8.775

View more
  4 in total

1.  Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up.

Authors:  Dragan Kalinić; Ranko Škrbić; Duško Vulić; Nataša Stojaković; Svjetlana Stoisavljević-Šatara; Miloš P Stojiljković; Vanda Marković-Peković; Ana Golić Jelić; Nataša Pilipović-Broćeta; Nathan D Wong; Brian Godman
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

2.  Variation in hypertension clinical practice guidelines: a global comparison.

Authors:  Richu Philip; Thomas Beaney; Nick Appelbaum; Carmen Rodriguez Gonzalvez; Charlotte Koldeweij; Amelia Kataria Golestaneh; Neil Poulter; Jonathan M Clarke
Journal:  BMC Med       Date:  2021-05-12       Impact factor: 8.775

3.  Diet Sugar-Free Carbonated Soda Beverage, Non-Caloric Flavors Consumption, and Diabetic Retinopathy: Any Linkage.

Authors:  Hyder Mirghani; Naif Alali; Hani Albalawi; Ruba ALselaimy
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-24       Impact factor: 3.168

4.  A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

Authors:  Abhinav Grover; Mansi Oberoi
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2020-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.